Preclinical News and Research

RSS
Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

28 Oct 2010
BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

28 Oct 2010
The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

28 Oct 2010
Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

28 Oct 2010
Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

27 Oct 2010
Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

27 Oct 2010
New International malaria research consortium to develop novel classes of antimalarials

New International malaria research consortium to develop novel classes of antimalarials

27 Oct 2010
HIFU technology effective for treating metastatic liver cancer

HIFU technology effective for treating metastatic liver cancer

27 Oct 2010
VCA Clinical Fellowship awarded for epithelial ovarian cancer research

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

27 Oct 2010
MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

27 Oct 2010
Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

27 Oct 2010
Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

26 Oct 2010
aTyr Pharma announces $23 million Series C equity financing

aTyr Pharma announces $23 million Series C equity financing

26 Oct 2010
Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

26 Oct 2010
Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

26 Oct 2010
Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

26 Oct 2010
NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

26 Oct 2010
Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

25 Oct 2010
Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

25 Oct 2010
NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

25 Oct 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback